论文部分内容阅读
目的观察华法林抗凝治疗非瓣膜性心房颤动(房颤)的临床应用效果。方法将176例非瓣膜性房颤患者按患者抗凝意愿分成治疗组和对照组各88例,治疗组口服华法林抗凝治疗,对照组口服阿司匹林抗血小板治疗。观察2组患者临床疗效,出现栓塞和出血情况及1年内随访脑卒中发生率。结果治疗组的总有效率为94.3%显著高于对照组的64.8%,脑栓塞、外周血管栓塞、左房附壁血栓、脑出血和其他部位出血的发生率均明显低于对照组。随访1年,治疗组1年内脑卒中发生率低于对照组,差异均有统计学意义(P<0.05)。结论采用华法林抗凝治疗非瓣膜性房颤能有效降低卒中发生率,具有临床推广价值。
Objective To observe the clinical effect of warfarin anticoagulation on non-valvular atrial fibrillation (atrial fibrillation). Methods One hundred and seventy-six patients with non-valvular atrial fibrillation were divided into treatment group and control group according to patients’ anticoagulation intention. The treatment group was treated with warfarin anticoagulant therapy and the control group was treated with aspirin antiplatelet therapy. The clinical efficacy, embolism and bleeding in the two groups were observed and the incidence of stroke was followed up within one year. Results The total effective rate of the treatment group was 94.3%, which was significantly higher than that of the control group (64.8%). The incidence of cerebral embolism, peripheral embolism, left atrium mural thrombosis, cerebral hemorrhage and other parts of bleeding were significantly lower than the control group. The follow-up of 1 year, the incidence of stroke within 1 year in the treatment group was lower than that in the control group, the differences were statistically significant (P <0.05). Conclusion Warfarin anticoagulant treatment of non-valvular atrial fibrillation can effectively reduce the incidence of stroke, with clinical value.